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Using a numerical integration method, concentration-time data were simulated using the 
one-compartment open model both with bolus intravenous administration and oral adminis- 
tration (first-order absorption) after multiple doses administered at constant time intervals and for 
each model for five different doses. Constants used produced data very similar to those which 
have been reported for phenytoin in the literature. In the simulation of oral data, sufficient 
concentrations were recorded to allow estimation of the maximum (C~a~), average (C~), and 
minimum (C~ in) concentrations during each dosage interval, but for the intravenous data only 
C~ ~ and C~ 'n values were recorded. The approach to steady state was monoexponential for low 
doses and biexponential for higher doses. The half-life of the final first-order approach to the 
steady-state concentration was approximately linearly related to the final steady-state concen- 
tration. For the intravenous data the number of doses required to reach 95% of C~ in was a linear 
function of O. 95 C'~ i". A simple difference plot allows any given steady.-state concentration of the 
three to be estimated from non-steady-state concentrations. When C~ '~ values are measured, as 
in therapeutic drug monitoring, the fitting of C~ in vs. dose rate (D/r) data leads to operationally 
useful parameters, V~  pp and K~m pp, which are not the true kinetic parameters, Vm and Kin, 
whereas fitting of C~ vs D/.c data does lead to estimation of Vm and Km. 
KEY WORDS: time to reach steady state; prediction of steady-state concentrations; 
Michaelis-Menten elimination kinetics. 
INTRODUCTION 
The Michaelis-Menten equation (1) was first applied in pharmaco- 
kinetics to explain elimination of ethanol from human serum by Lundquist 
and Wolthers (2). Other applications of the equation were summarized by 
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Wagner (3). More recently the equation has been applied to serum and 
plasma concentrations of phenytoin (4-7). Some properties of the equation 
and its integrated form were given by Wagner (8). Tsuchiya and Levy (9) 
published some plots of the ratio plateau level/dose vs. dose after simulat- 
ing multiple dose levels for the one-compartment open model with (a) 
first-order elimination, (b) Michaelis-Menten elimination, and (c) parallel 
first-order and Michaelis-Menten elimination. However, there appears to 
be no published information on the time required to reach steady-state 
levels when elimination obeys Michaelis-Menten kinetics. In the case of 
phenytoin monitoring, authors (5-7) are measuring a phenytoin concen- 
tration at some time within one or more dosage intervals, but differ as to 
when during the dosage interval the sample is taken or after how many 
doses. Eadie (10) states that the "5 times half-life rule works adequately" 
for phenytoin as for drugs eliminated by first-order kinetics. Intuitively, 
this appeared to be incorrect to this author. This study was undertaken to 
obtain quantitative information by a simulation technique concerning the 
time required to reach steady state and methods to predict steady-state 
concentrations from concentrations "observed" before steady-state was 
attained. 
THEORETICAL 
Equation 1 applies to the steady state for the one-compartment open 
model with constant-rate intravenous infusion and Michaelis-Menten 
elimination kinetics: 
ko = VaV,,,Css/(K,,, + Css) (1) 
where ko is the constant infusion rate (mass/time), Va is the volume of 
distribution, Vm is the maximal velocity [mass/(volume• so that 
VaVm is the maximal velocity (mass/time), Km is the Michaelis constant 
(mass/volume), and C~ is the steady-state concentration (mass/volume). 
For the n-compartment open mammillary model with central compart- 
ment elimination only, equation 1 also applies, but Va is replaced by Va~s 
as defined by 
gdss = (1 3r- k12/ k21 "Jr-'" + k ln/ k,1) Vp (2) 
where k12 and k21 are the transfer rate constants between compartments 1 
and 2, k~n and k,1 are the transfer rate constants between compartment 1 
and the nth compartment, and Vp is the volume of the central compart- 
ment. 
For intermittent intravenous administration with a dose D adminis- 
tered every ~- hr, equation 3 would apply, where the average steady-state 
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concentration, C'ss, is given by equation 4: 
D / 7  = VdVmCsJ(Km + Q~) (3) 
Io ~ = c ~ ( t )  dt/~- (4) 
Thus the k0 of equation 1 is replaced by the "dose rate," D/% in equation 3 
and C~ is replaced by tiffs. 
Analogously, for oral administration one would expect equations 3 
and 4 also to apply, since, as in linear pharmacokinetics, the absorption 
rate constant would not appear in such an equation; the only change would 
be that for oral administration the D of equation 3 would mean the amount 
of drug which reaches the circulation intact. 
In therapeutic drug monitoring the minimum concentrations (just 
before the next dose) are readily measured, but not the average concen- 
tration during any given dosage interval, since the latter require several 
blood samples, but th~ former require only one sample per dosage interval. 
One question to be answered by the study performed was whether equa- 
tion 3 applies if (~  is replaced by min rain Css , where C~ is the minimum 
concentration at steady state. 
EXPERIMENTAL 
Two sets of simulations were performed. In both cases the differential 
equations were numerically integrated using the Runge-Kutta method and 
an electronic calculator. Numerical values of the constants used were 
similar to some of those reported by Richens (5) for phenytoin. 
Simulated Intravenous Data 
Equation 5 was numerically integrated for each dosage interval: 
- dC/d t  = V,,C/(Km + C) (5) 
In equation 5, C is the simulated plasma concentration at time t after the 
nth dose of Size D and the other symbols are as defined in the Theoretical 
section. Constants used were Vm = 15 mg/(liters • Km = 12 mg/liter, 
D = 200, 250, 300, 400, and 500 mg, corresponding to Co = 5, 6.25, 7.5, 
10, and 12.5 mg/liter, respectively, since the assumed volume of dis- 
tribution, Vd, was 40 liters. The "dose" was given once a day, hence the 
dosage interval, ~" = 1 day, and the dose rates, D/T, were the same as the 
doses. The step height employed was 0.01 day. When D = 200, Co = 5 for 
the first day; for subsequent days, Co was equal to 5 plus the value of C at 
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24 hr after the previous dose. During these simulations, only the maxi- 
max rain mum, C~ , and minimum, C .  , concentrations for each dose were 
recorded, where n is the dose number. 
Simulated Oral Data 
Equation 6 was numerically integrated for each dosage interval: 
dC/dt = k~Co e - k ' -  VinCI(Kin .4- C) (6) 
where ka is the first-order rate constant for absorption and the other 
symbols are as defined above. Constants used were k, = 0.25 hr -a, Vm = 12 
mg/(liters x day), Km= 12 mg/liter, D = 100, 150, 300, 400, and 600, 
corresponding to Co--1.67, 2.5, 5, 6.67, and 10 mg/liter, respectively, 
since the assumed Va was 60 liters. Again ~-= 1 day, hence the dose rates 
were the same as the doses. During these simulations, the concentrations at 
0, 0.5, 1, 2, 4, 6, 8, 12, and 24 hr, as well as the maximum concentration, 
C m~, and the time of the maximum cocncentration, t m"~, were recorded for 
each dose. The average concentration during each dosage interval, C,, was 
estimated by estimating the area under the C, t curve [mg/(liters • hr)] by 
trapezoidal rule, then dividing this area by r (in this case 24 hr). 
Treatment ot Data 
Initial estimates of the asymptotic steady-state concentrations, Cs rain 
rain __ and C~, were obtained by extrapolating linear plots of C~ i" vs. C,+1 
C~ i" or C, vs. C ,+1-  C, (see later Fig. 2), since the concentrations were 
obtained at equal time intervals (11,12). Initial estimates of the rate 
parameters, A a and A2, were obtained by application of the back-projection 
C,,+1 - C .  or technique to the differences, rain min C n + l  - C n .  
Final estimates of the steady-state concentrations and the Ai's were 
rain obtained by nonlinear least-squares fitting of C.,n or C .  ,n data to one of 
equations 7-10, using the program NONLIN (13) and a high-speed digital 
computer. 
C. = Cs~(1 - e -~1") 
rain Aln Cm~B=C~ ( 1 - e  ) 
G = G ( 1  - e - ~ ' " )  + C~(1  - e -~=~) 





From equation 9 one obtains C~s = C1 + C2 for n ~ co and from equation 10 
one obtains C~ in = Ca + C2 for n -> oo. It should be noted, since n = 1, 2, 
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3 . . . .  , etc., days, that the A~'s have dimension day -1. In the fittings the 
concentrations were weighted 1/Ci  and A1 < A2. 
The half-life, (t1/2)al, corresponding to each estimated A1 value, was 
obtained by dividing the A 1 value into the natural logarithm of 2. For each 
data set these half-life values were plotted against the corresponding 
steady-state concentrations. 
The steady-state concentrations were also fitted, via NONLIN, to 
either equation 11 or 12, also with reciprocal weighting. 
Cs~ i" : Ka,, pp ( D / r ) / {  Vd U ~  p - (D/T)} (11) 
Gs =Km (19/~-)/{ Va Vm -- (D/~-)} (12) 
Equation 12 is just a rearranged form of equation 3. In equation 11, K ~  p 
and V~ p are operationally useful parameters, but are not the same as the 
Km and Vm used to generate the data. 
The parameters of equations 11 and 12 were also estimated by use of 
various linear transformations of the equations (14-18). 
R E S U L T S  
Figure 1 is a plot of the minimum concentration after the nth dose, 
r a i n  Cn , vs. the dose number, n, for the intravenous simulation. Similar plots 
(not shown) were obtained when C ma• from the intravenous simuhtions or 
C~ ax, Cn, and C~ in from the oral simulations were plotted vs. n. One can 
immediately perceive that the higher the dose, the higher the steady-state 
concentration and the longer the time required to reach that concentration. 
If concentrations are measured at equal time intervals, as in the 
simulations, the difference method, as introduced into pharmacokinetics by 
Amidon et al. (1 1), and modified by Wagner and Ayres (12), could be 
applied to estimate the asymptotic steady-state concentrations from data 
obtained before steady state was attained. Examples are shown in Fig. 2. 
During the monitoring of minimum phenytoin concentrations, similar plots 
to those illustrated in Fig. 2 could be constructed. In Fig. 2 the plots are 
linear since data of each set were chosen in the dose number range where 
the approach to steady state is described by single exponential function 
(equation 8). If all the data of a given set are described by a biexponential 
equation (equation 9 or 10) as n increases, e -A2n ~0 ,  hence the second 
term on the right-hand sides of equations 9 and 10 approaches (72 and the 
final approach is monoexponential in all cases. If all or essentially all data 
of a set where the entire approach is described by a biexponential equation 
are included in the difference plot, then the difference data may be fitted 
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Fig. L Plot of minimum concentration after the nth dose, C~ rain, vs, the 
dose number, n, for the intravenous simulation, Symbols and dose rates 
(D/z, g/day) are 0 ,  0.50; O, 0.4(I; <), 0.30; n ,  0.25; A, 0.20. 
top of Fig. 2 (solid circles) are part of the data shown at the bottom of Fig. 3 
(solid squares); in this case, using only the linear data of Fig. 2, the 
estimated C~ ~ is 19.29, and, using all the data, fitted by the parabola in 
Fig. 3, the estimated C~ in is 1,9.28. 
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Fig. 2. Application of the "difference method" to estimate asymptotic steady-state 
eoricentrations. Examples are from simulated intravenous data. Symbols and dose 
rates (D/,r, g/day) are O, 0.40; ~, 0.30; m, 0.25; 9 0.20. Numbers above the points 
are the dose numbers. Intercepts on the ordinate scale are the estimated C~ i" values. 
For.example, the equation of the line for the upper (0) set is C~ j~ = 19.29-7.057 
(C~+~ - C~'")~ hence C~" = 19.29. 
Once  estimates of the asymptotic  Css and C ~  ~ were obtained by the 
difference method,  then the In (Cs~-  C,) ,  t and In ( C ~  i" - c m i " ) ,  t data 
were analyzed.  It was found that the simulated data resulting from the two 
lowest  doses  were described by monoexponent ia l  equations (equation 7 or 
8), while data for the other doses  were described by a biexponential  
equation (equation 9 or 10). H e n c e  the low-dose  data were fitted to 
equations 7 and 8, and the higher-dose data were fitted to equations 9 and 
10 by nonlinear least-squares regression. Results  of the computer  fittings 
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Fig. 3. Fitting of two sets of "difference data" to the equation of a parabola. 
Examples are from simulated intravenous data. Symbols and dose rates (D/T, 
g/day)  are 9 0.5;  I I ,  0.4. For the upper curve the equation is C ~  i" = 5 0 . 0 4 - 1 9 . 1 8  
rain min rnin mm 2 9 mln 
( C . + 1  - C .  ) + 2 . 2 8 8  ( C . + :  - C .  ) , hence the est:mated Cs~ = 50.04.  For  the 
lower curve the equation is C ~  '" = 1 9 . 2 8 -  7 .233 (C.+am'" - C . ~  . . . . .  ) + 0 . 8 2 1 8  (C.+~ 
cml . )2 ,  hence the estimated C mi~ = 19.28. 
are shown in Table I. The monoexponential fittings were excellent, with 
almost all of the percent deviations being less than 1% and r z ( 1 -  
E dev2/Z obs 2) and Corr (correlation coefficient for the linear regression of 
t7" on Y) being equal to 1.000. Similarly, the biexponential fittings were 
excellent, with all percent deviations being less than 1% except those at 
very low dose numbers, and r 2 and Corr being equal to 1.000. 
Table II compares the asymptotic steady-state concentrations esti- 
mated by the computer-fitting method with those obtained by the 
difference method. Agreement is excellent in all 15 comparisons. 
The half-life obtained from the smaller rate parameter, A:, namely 
(tl/2)~1, is approxirhately linearly related to the steady-state concentration. 
This is illustrated in Fig. 4 with the Css data from the oral simulations. The 
author believes that the deviations from linearity are real and that the 
straight line is only an approximation to the trends in the data. Similar plots 
(not shown) for the Cs m:n data from both the intravenous and oral simula- 
tions also had similar deviations. The equations of the lines and correlation 
coefficients (r) are shown as equations 13 and 14. 
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Table I. Results  of Nonlinear  Least-Squares  Fitting of C'., n and C.~i~,n Data  
Data  
Steady-state 
Equat ion D/'r concentrat ion C~ C2 A~ ;t 2 
used (g/day) (rag/liter) (mg/liter) (mg/liter) (days -1) (days -1) 
Oral, C', 3 0.10 1.943 a - -  - -  0.7003 - -  
(0.00728) b (0.0108) 
3 0.15 3.157 a - -  - -  0.6333 - -  
(0.00551) (0.00531) 
5 0.30 8.481 ' ~  6.063 2.418 0.3451 0.8713 
(2.227) (2.271) (0.0674) (0.405) 
5 0.40 14.842 ' ~  9.604 5.238 0.2053 0.6116 
(1.159) (1.220) (0.0182) (0.0787) 
5 0.60 56.190 "~ 39.728 16.462 0.04509 0.2907 
(0.949) (2.368) (0.00821) (0.0300) 
Oral,  C ~  ~ 4 0.10 1.411 d - -  - -  0.7939 - -  
(0.00161) (0.00395) 
4 0.15 2.364 - -  - -  0.6950 - -  
(0.00304) (0.00459) 
6 0.30 6.910 a'~ 5.458 1.452 0.3569 1.072 
(0.0321) (0.0329) (0.00131) (0.0157) 
6 0.40 12.730 a'~ 5.985 6.745 0.1799 0.4445 
(2.923) (3.033) (0.0514) (0.0907) 
6 0.60 52.056 a'~ 39.431 12.625 0.04816 0.3511 
(0.567) (1.114) (0.00438) (0.0254) 
i.v., Ctr~ ain 4 0.20 3.829 u - -  - -  0.6457 - -  
(0.00750) (0.00626) 
4 0.25 5.792 - -  - -  0.5298 - -  
(0.0128) (0.00606) 
6 0.30 8.724 a'~ 10.952 - 2 . 2 2 7  0.3623 0.3390 
(6.655) (6.726) (0.2053) (0.8972) 
6 0.40 19.161 a'~ 14.797 4.364 0.1653 0.7245 
(0.121) (0.141) (0.00174) (0.0182) 
6 0.50 48.113 a'~ 39.793 8.319 0.06967 0.5146 
(0.131) (0.299) (0.00144) (0.0168) 
aValues of Css- 
bNumbers  in parentheses  are s tandard deviations of the est imated parameters .  
~G+c~. 
UValues of C ~  ~. 
Oral simulation: 
(tl/2)~ = 0.340 + 0.270Cs rain r = 0.9996 (13) 
Intravenous simulation: 
(tl/2)~ = 0.216 +0.203Cs  rain r = 0.9998 (14) 
In therapeutic drug monitoring it may be more  realistic to consider, say, 
95% of the steady-state concentration. Figure 5 is a plot of the number  of 
doses required to reach 95% of the minimum steady-state concentrat ion 
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Table II. Comparison of Steady-State Concentrations Estimated by Computer Fitting of All 
Of the Data of EachSet and Those Estimated by the Difference Method 
Steady-state concentration Data points used (n) 
D/T Difference Difference 
Data (g/day) Computer method Computer method 
Oral, (~n 
Oral, C ~  n 
i.v., C~ in 
0.10 1.943 1.934" 0-10 4-8 
0.15 3.157 3.153" 0-15 4-11 
0.30 8.481 8.516 a 0-16 8-16 
0.40 14.842 14.867 a 0-21 13-21 
0.60 56.190 56.26" 0-30 27-30 
0.10 1.411 1.413" 0-10 1-10 
0.15 2.364 2.367" 0-15 1-12 
0.30 6.910 6.914 '~ 0-16 9-16 
0.40 12.730 12.762 '~ 0-21 14-21 
0.60 52.056 51.868" 0-30 17-30 
0.20 3.829 3.843" 0-15 3-15 
(3.842) a'b (3-9) b 
0.25 5.792 5.822 a 0-20 4-20 
( 5 . 8 2 0 )  a (4-11) b 
0.30 8.724 8.636" 0-20 6-20 
(8.631)" (6-13) b 
0.40 19.161 19.288 a 0-20 11-20 
(19.278) c (1-20) c 
0.50 48.113 50.040 c 0-25 2-25 
aLinear plots (see examples in Fig. 2). 
bNumbers in parentheses in the fourth column are estimates made 
data points in parentheses in last column. 
CEstimates made by fitting of a parabola to the difference data. 
with the smaller number of 
vs. 0.95 Cs rain for  the  i n t r avenous  s imula t ion .  The  var iab les  a re  l inear ly  
r e l a t ed :  
rain 
no.95 = 2.15 + 0 . 8 2 7 ( 0 . 9 5 C s s  ) r = 1.00 (15) 
S imi lar  p lo ts  using d a t a  f rom the ora l  s imula t ions  d id  no t  exhib i t  as good  
l inear i ty ,  bu t  the  t r ends  were  the  same.  
F igu re  6 shows resul ts  of f i t t ing the  c o m p u t e r - d e r i v e d  va lues  of Cs~ ~" 
and  C~s f rom the  o ra l  s imula t ed  da t a  to equa t ions  11 and  12, respec t ive ly .  
The  e s t i m a t e d  p a r a m e t e r s  a re  shown in Tab le  I I I ,  whe re  they  are  
c o m p a r e d  with  e s t ima tes  m a d e  us ing var ious  l inea r  t r ans fo rma t ions  of 
equa t ions  11 and  12. C o m p u t e r  fi t t ing of the  C~, D/z d a t a  gave an 
e s t i m a t e d  va lue  of VaVm of 0.731 g / d a y ,  which c o r r e s p o n d s  to a 1/~ va lue  
of 12.18, which  is 1 .5% h igher  than  the  k n o w n  va lue  used  in the  s imula-  
t ion.  The  e s t ima ted  va lue  of Km was 12.23, which is 1 .9% h igher  than  the  
k n o w n  va lue  of 12. These  smal l  e r ro r s  could  r ead i ly  be  a c c o u n t e d  for  as a 
resul t  of  using the t r a p e z o i d a l  rule  to e s t ima te  the  a reas  f rom jus t  a few 
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Fig. 4. Plot of the half-life, (q/2)xl, from the smallest rate 
parameter, A1, vs. the average steady-state concentration, C'~, 
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points and the errors involved in the fitting~ Thus equation 12 does apply to 
oral data, and the true kinetic constants, V,, and Kin, are estimated. But in 
fitting of Cs~ , D / z  data, shown in Fig. 6, the estimated value the computer  ' rain 
of VdV~ p was 0.709, corresponding to a V ~  p value of 11.82, which is 
1.5% lower than the known value of Vm, and the estimated value of K ~  p 
was 9.45, which is 27% lower than the known value of Km of 12. Figure 7 
Css , D/~" data from the intravenous simulation shows the results of fitting rain 
to equation 11. The estimated parameters are shown in Table II1. The 
estimated value of ~1 l[Tapp vd~, ,  was 0.585, corresponding to an estimated value 
of V~, pp of 14.625, which is 2.5% lower than the known value of V,, of 15; 
the estimated value of Kam pp was  8 .25 ,  which is 31% lower than the Km 
value of 12. This explains why the " t rue"  kinetic constants, Vm and Kin, 
appear in equation 12, but only apparent constants, Va~ pp and Kam pp, appear 
in equation 11. Thus V "~pp and K ~  p are operationally useful parameters 
O ,m 30 
n-" 
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Fig. 5. Plot of the number of doses (n0.95) required to reach 95% 
of the minimum steady-state concentration vs. 95% of the 
minimum steady-state concentration using data from the 
intravenous simulation. Equation of the line is in the text 
(equation 11). 
derived from minimum steady-state concentrations, but are not the actual 
enzyme constants. This, therefore, applies to the same type of constants 
reported by Richens (5), Ludden et al. (6), and Mullen (7). It is also of 
interest to see, in some cases, how much the constants estimated by other  
methods differ from those estimated by nonlinear least-squares fitting 
(Table III). 
D I S C U S S I O N  
The simulations have shown that when elimination kinetics is that 
of Michaelis and Menten the rate of accumulation is either mono- or bi- 
exponential, with the half-life corresponding to the smaller rate parameter  
being approximately linearly related to the final steady-state concen- 
tration. Thus, as the dose rate is increased, it requires proportionately 
more time to reach a given proportion of the final steady-state concen- 
tration. Since parallel Michaelis-Menten metabolite formation paths (19) 
and parallel Michaelis-Menten and first-order elimination pathways (20) 
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Fig. 6. Results of nonlinear least-squares fitting of simulated oral data to equations 7 
and 8. & &, Css data (equation 8); 0----O, C~ in data (equation 7). See Table III 
for estimated parameters. 
frequently act like "pooled" Michael i s -Menten paths, the results of  these 
simulations have even broader applicability than just to simple Michael is -  
Menten  elimination. It was also found that the difference method  (see Figs. 
2 and 3) could be applied to the C ~  a~, n data generated in both the oral 
and intravenous simulations to estimate C ~  ax values. The latter values 
were also well fitted to an equation analogous to equation 11 except that 
vapp ~ . , - a p p  C max~ replaced C min'ss , in these cases, the _ , ,  and . . , ,  values which were 
estimated were different from those estimated from the corresponding 
C ~  in data. 
T h e  results of  this study indicate that the statement of Eadie (10) with 
respect to the rate of  accumulation of phenytoin is incorrect. In the moni-  
toring of phenytoin serum concentrations,  different investigators appear to 
have been allowing different times before measuring what they call 
"steady-state concentrations." Richens (5) stated: "The min imum 
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Table IlL Parameters Estimated by Computer Fitting of Data to Equation 11 and 12 or by 
Use of Various Linear Transformations of Those Equations 
Variables for plot 
V d V m  a K m  b 
Data Method Abscissa Ordinate (g/day) (mg/liter) 
Oral, Cs~ Computer fitting with D/'r C~ 0.731 12.23 
equation 12 (0.00047) (0.0367) 
Oral, C~ in 
i.v., c~is "n 
Cornish-Bowden and Css D/'r 0.731 12.25 
Eisenthal (14) c 
Lineweaver-Burk (15) 1/Css 1/(D/'r) 0.693 11.07 
Woolf (16) r (;ss/(D/'r) 0.731 12.23 
Eadie (17) (D/.r)/C~ 19/r 0.731 12.23 
Scatchard (18) D/'r (D/"r)/ff;ss 0.731 12.23 
Vd V~  p K ~ P 
(g/day) (mg/liter) 
Computer fitting with D/,c C~ in 0.709 9.45 
equation 11 (0.0047) (0.347) 
Cornish-Bowden and C mi" D/'r 0.654 8.08 
Eisenthal (14) 
Lineweaver-Burk (15) 1/C.~ in 1~(D/T) 0.653 7.85 
Woolf (16) C 2 1 "  cmi"/(D/'r) 0.701 8.95 
Eadie (17) (D/ ' r ) /C rain D/r 0.681 8.39 
Scatchard (18) D/'r (D/'r)/C~ n 0.681 8.39 
Computer fitting with 0.585 a 8.25 
equation 11 (0.0078) (0.519) 
Cornish-Bowden and See 0.548 6.95 
Eisenthal (14) directly 
Lineweaver-Burk (15) above 0.546 6.75 
Woolf (16) 0.578 7.80 
Eadie (17) 0.559 7.12 
Scatchard (18) 0.562 7.2/ 
aActual value used in the simulation was (60 x 12)/1000 = 0.720 g/day. 
bActual value used in the simulation was 12 mg/liter. 
CTheir equations 5 and 6 were used with all possible pairs of values; the reported value is 
the median. 
aActual value used in the simulation was (40 x 15)/1000 = 0.600 g/day. 
in fo rmat ion  needed  is one  accurate  s e rum level es t imat ion  in s teady state, 
i.e. after at least 2 weeks on a cons tan t  in take  of the drug. The  t ime of day 
at which the sample  is t aken  has no t  b e e n  al lowed for because  pheny to in  is 
absorbed  and  metabol ized  relat ively slowly. The  usual  f luctuat ion in se rum 
levels seen th roughout  the day se ldom exceeds 20%,  par t icular ly  at 
therapeut ic  se rum levels."  L u d d e n  et al. (6) stated: "Steady state se rum 
pheny to in  levels were de t e rmined  at least 3 bu t  usual ly 4 wk after a change  
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Fig. 7o Results of nonlinear least-squares fitting of simulated 
intravenous data to equation 7. See Table III for estimated 
parameters. 
in phenytoin dosage." The simulations show that the time that needs to be 
allowed depends on the dose rate of the drug. 
If one wishes to estimate --mvapp and ~-,,~Tapp for a given patient, as done 
by Richens (5), Ludden et al.. (6), and Mullen (7), then the simulations 
suggest a procedure as follows. Minimum steady-state concentrations, 
Inin C ,  , just before the next dose, should be measured on consecutive days, 
starting about 4-6 days after uniform therapy has been initiated or a 
change in dosage regimen has taken place. A difference plot should be 
prepared; if the difference data are linear (like the data in Fig. 2), then an 
estimate of Cs mix for a given dose rate is readily made. If the dose rate is 
high and/or  data are collected too early, the difference plot may be curved 
(like data in Fig. 3), in which case one may either fit a parabola to make an 
estimate of Cs~ 'n or keep collecting data until the plot becomes linear, then 
extrapolate the linear portion. Thus the pharmacokinetic equations (e.g., 
equation 11) require estimates of Cs~ in for various D/'r values; use of just 
some C mln values, as apparently has been done to date, would lead to 
biased results. 
Assay error involved in measurement of the C ,  ~i" values does not 
C ,  , n values necessarily lead to errors in estimated parameters. A set of min 
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was generated with equation 8 using Cs~ in = 100 and A1 =0 .1 ,  then 5% 
random error was added so that values were either 95% ( - e r r o r )  or 105% 
(+er ror )  of the actual C rain values; for n = 1, 2, 3, 4, 7, 10, 15, 20, 25, and 
30, the error was - ,  + ,  + ,  - ,  + ,  , , + ,  - ,  and + ,  respectively. 
Compute r  fitting of the C7  in data with the 5% random error to equation 
11 gave estimates as follows: Csn~ in = 100.00 and A1 = 0.1000. Thus with 
inclusion of 5% random error in the data the theoretical constants were 
exactly estimated. 
It  is interesting that the K ~  p values, est imated f rom Cs~ in values, are 
quite different than the actual Km values, while the Vam pp values, estimated 
f rom Cs rain values, are only slightly different than the actual Vm values. 
Also, estimates of V d V ~  p and K ~  p, obtained by the method of Cornish-  
Bowden and Eisenthal and via various linear transformations of equations 
11 f rom C~  in data, were all lower than estimates of the same parameters  
obtained by nonlinear least-squares fitting with reciprocal weighting. 
However ,  estimates of VaV,,  and Km obtained by all methods agreed quite 
well except those obtained via the double reciprocal or L ineweaver -Burk  
(15) transformation,  which gave the lowest estimates in each case. 
In the simulations the ratio . . . .  in C~ / C ~  was always highest for n = 1; 
then as n increased the ratio decreased and approached an asymptotic 
value at higher values of n. The asymptotic value of the ratio was lower the 
higher the dose. For the intravenous data the asymptotic ratios were 2.30, 
1.87, 1.53, 1.29, and 1.15 for dose rates of 0.2, 0.3, 0.4, 0.5, and 0.6, 
respectively. For the oral data the asymptotic ratios were 1.58, 1.54, 1.38, 
1.28, and 1.12 for dose ratios of 0.1, 0.15, 0.3, 0.4, and 0.6 g/day,  
respectively. Hence in the monitoring of phenytoin serum concentrations 
one would expect the degree of fluctuation in the concentrations 
throughout the day to be both dose and concentration dependent.  These 
data support  measurement  of minimum concentrations just before the next 
dose. 
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